| Title |
C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy
|
|---|---|
| Published in |
BMC Cancer, August 2012
|
| DOI | 10.1186/1471-2407-12-337 |
| Pubmed ID | |
| Authors |
Hiroki Ito, Koichi Shioi, Takayuki Murakami, Akitoshi Takizawa, Futoshi Sano, Takashi Kawahara, Nobuhiko Mizuno, Kazuhide Makiyama, Noboru Nakaigawa, Takeshi Kishida, Takeshi Miura, Yoshinobu Kubota, Masahiro Yao |
| Abstract |
C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the onset, is not well studied. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 19% |
| Researcher | 3 | 14% |
| Student > Doctoral Student | 2 | 10% |
| Student > Postgraduate | 2 | 10% |
| Student > Master | 2 | 10% |
| Other | 5 | 24% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 57% |
| Biochemistry, Genetics and Molecular Biology | 3 | 14% |
| Nursing and Health Professions | 1 | 5% |
| Unspecified | 1 | 5% |
| Unknown | 4 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2012.
All research outputs
#14,148,857
of 22,673,450 outputs
Outputs from BMC Cancer
#3,347
of 8,243 outputs
Outputs of similar age
#96,100
of 164,813 outputs
Outputs of similar age from BMC Cancer
#37
of 83 outputs
Altmetric has tracked 22,673,450 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,243 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,813 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.